SML0216
布林佐胺
≥98% (HPLC)
别名:
AL 4862, （5R）-5-乙基氨基-3-（3-甲氧基丙基）-2,2-二氧代-2?6,9-二硫杂-3-氮杂双环[4.3.0]壬-7,10-二烯-8-磺酰胺, （R）-4-（乙基氨基）-3,4-二氢-2-（3-甲氧基丙基）-2H-噻吩并[3,2-e] -1,2-噻嗪-6-磺酰胺1,1-二氧化物
登录查看公司和协议定价
关于此项目
经验公式（希尔记法）:
C12H21N3O5S3
CAS Number:
分子量:
383.51
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
储存条件
desiccated
颜色
white to beige
溶解性
DMSO: ≥10 mg/mL
储存温度
−20°C
SMILES字符串
CCN[C@H]1CN(CCCOC)S(=O)(=O)c2sc(cc12)S(N)(=O)=O
InChI
1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChI key
HCRKCZRJWPKOAR-JTQLQIEISA-N
基因信息
human ... CA2(760)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
布林佐胺是一种小分子量的化合物，能结合黑色素。该药可用于眼部治疗。
应用
在黑色素结合测定中，布林佐胺已被用作黑色素结合化合物或药物。它也被用作碳酸酐酶抑制剂（CAI）。
生化/生理作用
布林佐胺是一种用于降低眼压的碳酸酐酶 II 抑制剂。
布林佐胺是碳酸酐酶 II 抑制剂
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Louis F Dell'osso et al.
Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 31(3), 228-233 (2011-06-29)
Recent advances in infantile nystagmus syndrome (INS) surgery have uncovered the therapeutic importance of proprioception. In this report, we test the hypothesis that the topical carbonic anhydrase inhibitor (CAI) brinzolamide (Azopt) has beneficial effects on measures of nystagmus foveation quality
Ivan Goldberg et al.
Journal of glaucoma, 21(1), 55-59 (2010-11-05)
To compare the efficacy of brinzolamide versus placebo when added to travoprost/timolol fixed combination (TTFC) in uncontrolled patients. This was a prospective, double-masked, randomized, placebo-controlled, parallel comparison of ocular hypertensive or primary open-angle glaucoma patients. Patients treated with a prostaglandin-based
Gemma Caterina Maria Rossi et al.
Expert opinion on pharmacotherapy, 12(5), 685-690 (2011-03-10)
To examine the impact of switching glaucoma patients from timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination (Brinz/Tim FC) on quality of life and on ocular surface status; to assess efficacy after the switch. 6-month, multicenter, open-label, prospective, switch study
John H K Liu et al.
Ophthalmology, 118(10), 1995-2000 (2011-06-17)
A core assumption for the 1-eye therapeutic trial of ocular hypotensive medications is the symmetrical reduction of intraocular pressure (IOP) in paired eyes. This assumption was evaluated for 24-hour IOP reduction in patients who underwent monotherapy or adjunctive therapy. Database
Constantine D Georgakopoulos et al.
Clinical & experimental ophthalmology, 41(7), 662-667 (2013-02-26)
To evaluate the efficacy of brinzolamide-timolol fixed combination in intraocular pressure during the first 24 h after uneventful phacoemulsification cataract surgery using Viscoat and Provisc. Prospective randomized comparative case series. Ninety-two eyes of equal patients scheduled for phacoemulsification cataract surgery. Treatment
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持